>
AFT Pharmaceuticals logo

AFT - AFT Pharmaceuticals Share Price

NZD4.81 0.0  0.2%

Last Trade - 6:00am

Sector
Healthcare
Size
Small Cap
Market Cap £258.2m
Enterprise Value £277.9m
Revenue £55.3m
Position in Universe 436th / 1907
Bullish
Bearish
Unlock AFT Revenue
Momentum
Relative Strength (%)
1m +6.45%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -15.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
56.2 64.0 69.2 81.2 85.1 105.6 113.3 135.1 +13.4%
+288.4 +122
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 September 2020, AFTPharmaceuticals Ltd revenues increased 4% to NZ$48.8M. Netincome decreased 88% to NZ$1.2M. Revenues reflect Australiasegment increase of 11% to NZ$28.6M, New Zealand segmentremaining flat at NZ$13.7M, Australia segment increase of11% to NZ$28.6M, New Zealand segment remaining flat atNZ$13.7M. Net income was offset by Gain on derecognition ofequity accounte decrease from NZ$9.8M (income) to NZ$0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AFT
Graphical History

Revenue

AFT Revenue Unlock AFT Revenue

Net Income

AFT Net Income Unlock AFT Revenue

Normalised EPS

AFT Normalised EPS Unlock AFT Revenue

PE Ratio Range

AFT PE Ratio Range Unlock AFT Revenue

Dividend Yield Range

AFT Dividend Yield Range Unlock AFT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AFT EPS Forecasts Unlock AFT Revenue
Profile Summary

AFT Pharmaceuticals Limited is a pharmaceutical distributor and developer of pharmaceutical intellectual property. The Company's segments include New Zealand, Australia, Asia and Rest of World. The Company's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The Company's NasoSURF Nebuliser is in pilot scale production. The Company is focused on conducting clinical for Maxigesic oral dose forms. The Company is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.

Directors
Last Annual March 31st, 2020
Last Interim September 30th, 2020
Incorporated September 4, 1997
Public Since December 22, 2015
No. of Shareholders: 1,337
No. of Employees: 86
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange New Zealand Stock Exchange
Shares in Issue 104,578,875
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AFT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AFT
Upcoming Events for AFT
Sunday 23rd May, 2021
Full Year 2021 AFT Pharmaceuticals Ltd Earnings Call
Tuesday 7th September, 2021 Estimate
AFT Pharmaceuticals Ltd Annual Shareholders Meeting
Frequently Asked Questions for AFT Pharmaceuticals
What is the AFT Pharmaceuticals share price?

As of 6:00am, shares in AFT Pharmaceuticals are trading at NZD4.81, giving the company a market capitalisation of £258.2m. This share price information is delayed by 15 minutes.

How has the AFT Pharmaceuticals share price performed this year?

Shares in AFT Pharmaceuticals are currently trading at NZD4.81 and the price has moved by 14.01% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the AFT Pharmaceuticals price has moved by -14.96% over the past year.

What are the analyst and broker recommendations for AFT Pharmaceuticals?

Of the analysts with advisory recommendations for AFT Pharmaceuticals, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for AFT Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will AFT Pharmaceuticals next release its financial results?

AFT Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the AFT Pharmaceuticals dividend yield?

AFT Pharmaceuticals does not currently pay a dividend.

Does AFT Pharmaceuticals pay a dividend?

AFT Pharmaceuticals does not currently pay a dividend.

When does AFT Pharmaceuticals next pay dividends?

AFT Pharmaceuticals does not currently pay a dividend.

How do I buy AFT Pharmaceuticals shares?

To buy shares in AFT Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of AFT Pharmaceuticals?

Shares in AFT Pharmaceuticals are currently trading at NZD4.81, giving the company a market capitalisation of £258.2m.

Where are AFT Pharmaceuticals shares listed? Where are AFT Pharmaceuticals shares listed?

Here are the trading details for AFT Pharmaceuticals:

Country of listing: New Zealand
Exchange: NZC
Ticker Symbol: AFT
What kind of share is AFT Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, AFT Pharmaceuticals is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a AFT Pharmaceuticals share price forecast 2021?

Shares in AFT Pharmaceuticals are currently priced at NZD4.81. At that level they are trading at 3.17% discount to the analyst consensus target price of 0.00.

Analysts covering AFT Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of 0.082 for the next financial year.

How can I tell whether the AFT Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AFT Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -19.31%. At the current price of NZD4.81, shares in AFT Pharmaceuticals are trading at 0.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the AFT Pharmaceuticals PE Ratio?

The AFT Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 0.165k. The shares are currently trading at NZD4.81.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of AFT Pharmaceuticals?

AFT Pharmaceuticals's management team is headed by:

David Flacks - NEC
Hartley Campbell Atkinson - CEO
Marree Atkinson - EDR
Jon Lamb - NID
John Wilson - NID
Malcolm Dennis Tubby - CFO
Ioana Stanescu - OTH
Vladimir Ilievski - OTH
Brendon Woodhead - OTH
Murray Keith - OTH
Calvin Mackenzie - GMG
Scott Crawford - OTH
Louise Clayton - OTH
Anita Baldauf - NID
Ted Witek - NID
Who are the major shareholders of AFT Pharmaceuticals?

Here are the top five shareholders of AFT Pharmaceuticals based on the size of their shareholding:

Atkinson (Hartley Campbell) Individual Investor
Percentage owned: 69.46% (72.0m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2.13% (2.21m shares)
Statens Pensjonsfond Utland Mutual Fund
Percentage owned: 2.13% (2.21m shares)
Forsyth Barr Investment Management Limited Investment Advisor
Percentage owned: 1.56% (1.62m shares)
Hama Holdings Limited Corporation
Percentage owned: 0.84% (868k shares)
Similar to AFT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.